Cubist Systematic Strategies LLC Reduces Position in Evolus, Inc. (NASDAQ:EOLS)

Cubist Systematic Strategies LLC decreased its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 80.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 47,438 shares of the company's stock after selling 194,604 shares during the period. Cubist Systematic Strategies LLC owned 0.07% of Evolus worth $524,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Principal Financial Group Inc. increased its position in Evolus by 9.8% during the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock worth $368,000 after buying an additional 2,989 shares in the last quarter. Barclays PLC increased its position in Evolus by 12.9% during the fourth quarter. Barclays PLC now owns 105,786 shares of the company's stock worth $1,167,000 after buying an additional 12,124 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Evolus during the fourth quarter worth $575,000. JPMorgan Chase & Co. increased its position in Evolus by 63.5% during the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company's stock worth $2,753,000 after buying an additional 65,972 shares in the last quarter. Finally, IFP Advisors Inc increased its position in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after buying an additional 4,709 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on EOLS shares. Barclays raised their price target on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. BTIG Research initiated coverage on Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $23.75.

Insider Activity

In related news, insider Rui Avelar sold 3,385 shares of Evolus stock in a transaction on Monday, May 12th. The stock was sold at an average price of $9.87, for a total value of $33,409.95. Following the transaction, the insider now owns 359,082 shares in the company, valued at approximately $3,544,139.34. This trade represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Moatazedi sold 15,787 shares of Evolus stock in a transaction on Monday, May 12th. The shares were sold at an average price of $9.87, for a total value of $155,817.69. Following the completion of the transaction, the insider now owns 492,832 shares in the company, valued at $4,864,251.84. The trade was a 3.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 86,241 shares of company stock valued at $1,048,666 over the last quarter. Company insiders own 5.90% of the company's stock.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $10.00 on Friday. The company has a market cap of $644.76 million, a P/E ratio of -10.99 and a beta of 1.11. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82. The business has a fifty day simple moving average of $11.38 and a 200-day simple moving average of $12.41.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.